AR053189A1 - DERIVED FROM 5H- BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES - Google Patents

DERIVED FROM 5H- BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES

Info

Publication number
AR053189A1
AR053189A1 ARP060101120A ARP060101120A AR053189A1 AR 053189 A1 AR053189 A1 AR 053189A1 AR P060101120 A ARP060101120 A AR P060101120A AR P060101120 A ARP060101120 A AR P060101120A AR 053189 A1 AR053189 A1 AR 053189A1
Authority
AR
Argentina
Prior art keywords
groups
group
alkyl
atoms
optionally substituted
Prior art date
Application number
ARP060101120A
Other languages
Spanish (es)
Inventor
Hartmut Rehwinkel
Duy Nguyen
Markus Berger
Heike Schacke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR053189A1 publication Critical patent/AR053189A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esteroisomeros, procedimientos para su preparacion, preparados farmacéuticos y a su uso como antiinflamatorios. Reivindicacion 1: compuestos de la formula general (1) en donde R1 y R2 son, de modo independiente entre sí, un átomo de H, un grupo hidroxi, halogeno, alquilo C1-10 opcionalmente sustituido, alcoxi C1-10, alquiltio C1-10, perfluoroalquilo C1-5, ciano, nitro o R1 y R2 son juntos un grupo seleccionado de los grupos -O-(CH2)n-O-, -O-(CH2)n-CH2-, -O-CH=CH-, -(CH2)n+2-, -NH-(CH2)n+1- , -N(alquil C1-3)-(CH2)n+1-, -NH-N=CH-, en donde n = 1 o 2 y los átomos terminales están unidos con átomos de C del anillo directamente adyacentes, o NR8R9, en donde R8 y R9 pueden ser, de modo independiente entre sí, alquilo C1-5 o (CO)-alquilo C1- 5, R11 es un átomo de H, un grupo hidroxi, halogeno, ciano, alquilo C1-10 opcionalmente sustituido, alcoxi C1-10, alquiltio C1-10, perfluoroalquilo C1-5, R12 es un átomo de H, un grupo hidroxi, halogeno, ciano, alquilo C1-10 opcionalmente sustituido, alcoxi C1-10, R3 es un grupo alquilo C1-10 que opcionalmente puede estar sustituido con un grupo seleccionado de 1-3 grupos hidroxi, átomos de halogeno o 1-3 grupos alcoxi C1-5, cicloalquilo C3-7 opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo mono- o bicíclico que opcionalmente contiene 1-3 átomos de N y/o 1-2 átomos de O y/o 1-2 átomos de S y/o 1-2 grupos ceto, opcionalmente sustituido con no o varios grupos seleccionados de alquilo 1-5 (que a su vez pueden estar opcionalmente sustituidos con 1-3 grupos hidroxi o 1-3 grupos COOR10, en donde R10 es cualquier grupo protector de hidroxi, bencilo o alquilo C1-10, alcoxi C1-5, átomos de halogeno, grupos exometileno, en donde estos grupos pueden estar unidos con la amina del sistema de 5H-benzociclohepteno a través de cualquier posicion y opcionalmente pueden estar hidrogenados en no o varios sitios; A es un grupo -CR6R7-CH2- o -CH2-CR6R7-; D s un grupo -CR4R5-CH2- o -CH2-CR4R5; R4 es un grupo hidroxi OR10 o O(CO)R10; R5es un grupo alquilo C1-5, o alquilo C1-5 opcionalmente fluorado de forma total o parcial, cicloalquilo C3-7, alquilen C1-8-cicloalquilo C3-7 alquenilen C2-8-cicloalquilo C3-7, heterociclilo, alquilenheterociclilo C1-8, alquenilenheterociclilo C2-8, arilo, alquilenarilo C1-8, alquenilenarilo C2-8, alquinilenarilo C2-8, heteroarilo mono- o bicíclico que contiene 1-3 átomos de N y/o 1-2 átomos de O y/o 1-2 átomos de S opcionalmente sustituido con 1-2 grupos ceto, 1-2 grupos alquilo C1-5, 1-2 grupos alcoxi C1-5, 1-3 átomos de halogeno, 1-2 grupos exometileno, un grupo alquilenheteroarilo C1-8 o un grupo alquenilenheteroarilo C2-8, en donde estos grupos pueden estar unidos a través de cualquier posicion con el sistema de 5H-benzociclohepteno y opcionalmente pueden estar hidrogenados en uno varios sitios, R6 y R7 son, de modo independiente entre sí, un átomo de H, un grupo metilo o etilo o junto con el átomo de C del sistema de 5H-benzociclohepteno son un anillo cicloalquilo C3-6.Steroisomers, procedures for their preparation, pharmaceutical preparations and their use as anti-inflammatories. Claim 1: compounds of the general formula (1) wherein R1 and R2 are, independently from each other, an H atom, an optionally substituted hydroxy, halogen, C1-10 alkyl, C1-10 alkoxy, C1- alkylthio group 10, C1-5 perfluoroalkyl, cyano, nitro or R1 and R2 are together a group selected from the groups -O- (CH2) nO-, -O- (CH2) n-CH2-, -O-CH = CH-, - (CH2) n + 2-, -NH- (CH2) n + 1-, -N (C1-3 alkyl) - (CH2) n + 1-, -NH-N = CH-, where n = 1 or 2 and the terminal atoms are linked with directly adjacent C ring atoms, or NR8R9, where R8 and R9 can be, independently of one another, C1-5 alkyl or (CO) -C1-5 alkyl, R11 is an H atom, a hydroxy group, halogen, cyano, optionally substituted C1-10 alkyl, C1-10 alkoxy, C1-10 alkylthio, C1-5 perfluoroalkyl, R12 is an H atom, a hydroxy group, halogen, cyano, optionally substituted C1-10 alkyl, C1-10 alkoxy, R3 is a C1-10 alkyl group that may optionally be substituted with a selected group or of 1-3 hydroxy groups, halogen atoms or 1-3 C1-5 alkoxy groups, optionally substituted C3-7 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, mono- or bicyclic heteroaryl which optionally contains 1-3 N atoms and / or 1-2 atoms of O and / or 1-2 atoms of S and / or 1-2 keto groups, optionally substituted with no or several groups selected from alkyl 1-5 (which in turn may be optionally substituted with 1-3 hydroxy groups or 1-3 COOR10 groups, wherein R10 is any protecting group of hydroxy, benzyl or C1-10 alkyl, C1-5 alkoxy, halogen atoms, exomethylene groups, where these groups can be linked with the 5H-benzocycloheptene system amine through any position and may optionally be hydrogenated at no or several sites; A is a group -CR6R7-CH2- or -CH2-CR6R7-; D s a group -CR4R5-CH2- or -CH2-CR4R5; R4 is a hydroxy group OR10 or O (CO) R10; R5 is a C1-5 alkyl group, or optionally fully or partially fluorinated C1-5 alkyl, C3-7 cycloalkyl, C1-8 alkylene C3-7 cycloalkyl C3-7 alkenylene, heterocyclyl, C1- alkyleneheterocyclyl 8, C2-8 alkenyleneheterocyclyl, aryl, C1-8 alkylenyl, C2-8 alkenylenyl, C2-8 alkynylenyl, mono- or bicyclic heteroaryl containing 1-3 N atoms and / or 1-2 O atoms and / or 1 -2 S atoms optionally substituted with 1-2 keto groups, 1-2 C1-5 alkyl groups, 1-2 C1-5 alkoxy groups, 1-3 halogen groups, 1-2 exomethylene groups, a C1- alkyleneheteroaryl group 8 or a C2-8 alkenyleneheteroaryl group, where these groups can be linked through any position with the 5H-benzocycloheptene system and optionally can be hydrogenated at one of several sites, R6 and R7 are, independently of one another, a H atom, a methyl or ethyl group or together with the C atom of the 5H-benzocycloheptene system are a C3-6 cycloalkyl ring.

ARP060101120A 2005-03-22 2006-03-22 DERIVED FROM 5H- BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES AR053189A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005014090A DE102005014090A1 (en) 2005-03-22 2005-03-22 5H-Benzocycloheptender derivatives, process for their preparation and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
AR053189A1 true AR053189A1 (en) 2007-04-25

Family

ID=36589218

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101120A AR053189A1 (en) 2005-03-22 2006-03-22 DERIVED FROM 5H- BENZOCICLOHEPTENO, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES

Country Status (13)

Country Link
EP (1) EP1863765A1 (en)
JP (1) JP2008534462A (en)
CN (1) CN101146773A (en)
AR (1) AR053189A1 (en)
CA (1) CA2598969A1 (en)
DE (1) DE102005014090A1 (en)
DO (1) DOP2006000065A (en)
GT (1) GT200600124A (en)
PA (1) PA8666801A1 (en)
PE (1) PE20061350A1 (en)
TW (1) TW200700389A (en)
UY (1) UY29435A1 (en)
WO (1) WO2006100099A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196486A (en) * 2016-02-15 2023-04-17 Sanofi Sa 6,7-Dihydro-5h-Benzo[7]Annulene Derivatives as Estrogen Receptor Modulators
CN107118173B (en) * 2017-07-12 2019-10-29 阿里生物新材料（常州）有限公司 A kind of cycloheptatriene and oxazine compound and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
EP0368866A1 (en) * 1987-05-15 1990-05-23 Schering Corporation Aryl substituted naphthalene, benzoxepine, benzazepine, benzocycloheptene derivatives
CA1327796C (en) * 1987-07-16 1994-03-15 Jorg Senn-Bilfinger Diazoles
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
MXPA05007937A (en) * 2003-02-07 2005-09-30 Warner Lambert Co Oxazolidinone derivatives n-substituted by a bicyclic ring, for use as antibacterial agents.

Also Published As

Publication number Publication date
JP2008534462A (en) 2008-08-28
PE20061350A1 (en) 2006-12-20
GT200600124A (en) 2007-01-03
EP1863765A1 (en) 2007-12-12
CN101146773A (en) 2008-03-19
UY29435A1 (en) 2006-10-02
CA2598969A1 (en) 2006-09-28
WO2006100099A1 (en) 2006-09-28
TW200700389A (en) 2007-01-01
DOP2006000065A (en) 2006-10-15
DE102005014090A1 (en) 2006-09-28
PA8666801A1 (en) 2006-09-22

Similar Documents

Publication Publication Date Title
AR046062A1 (en) DERIVATIVES OF TETRAHYDRONAFTALENE PROCEDURE FOR PREPARATION AND ITS ANTI-INFLAMMATORY USE
AR055016A1 (en) TRICYCLE AMINOALCOHOLES, PROCEDURES FOR THE PREPARATION AND USE FOR THE PREPARATION OF MEDICINES
PE20130375A1 (en) TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINE COMPOUNDS, C-MET INHIBITORS AND COMPOSITIONS THEREOF
AR063015A1 (en) DERIVATIVES OF QUINAZOLINONA 5-SUBSTITUTE AND COMPOSITIONS THAT INCLUDE THEM AND METHODS TO USE THEM IN THE TREATMENT OF CANCER
PE20181304A1 (en) INDEOL N-SUBSTITUTE DERIVATIVES AS MODULATORS OF PGE2 RECEPTORS
AR073079A1 (en) TRIAZOLOPIRIDINE COMPOUNDS AS PIM CINASA INHIBITORS
AR081932A1 (en) DERIVATIVES OF HETEROARIL IMIDAZOLONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF NEOPLASIC AND AUTOINMUNE DISEASES
AR080187A1 (en) PIRAZOLIC DERIVATIVES CONDENSED WITH USEFUL NITROGEN HETEROYCLES IN THE TREATMENT OF INFLAMMATORY, IMMUNITY AND / OR MIELOPLOLIFERATIVE DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AR050733A1 (en) DERIVATIVES OF ALQUILIDEN-TETRAHIDRONAFTALENO, PROCEDURE FOR ITS PREPARATION AND ITS USE AS ANTI-INFLAMMATORIES
AR056949A1 (en) DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS AN INFLAMMATION INHIBITOR
PE20141678A1 (en) INDAZOL-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT / B-CATENIN SIGNALING PATHWAY
AR098872A1 (en) GPR6 TETRAHYDROPIRIDOPIRAZIN MODULATORS
PE20080841A1 (en) QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO STRESS OR DEPRESSION
AR072016A1 (en) ISOXAZOL DERIVATIVES THAT WORK AS POTENTIALS OF GLUTAMATE RECEIVERS
AR057380A1 (en) CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE AND THERAPEUTIC USE OF THE SAME
AR052943A1 (en) DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE
AR085489A1 (en) DERIVATIVES OF TRIAZOLOPIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM, INTERMEDIARIES OF SUCH PROCESS AND USE OF THE SAME FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
RS53061B (en) Protein kinase inhibitors
AR077977A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
PE20130155A1 (en) ARYLETINYL DERIVATIVES
AR072969A1 (en) CICLOHEXILAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES AS ANTAGONISTS OF THE RECEIVER OF THE CORTICOTROPINE RELEASE FACTOR (CRF - 1)
AR077362A1 (en) COMPOUNDS THAT SELECTLY MODULATE THE CB2 RECEIVER
AR078171A1 (en) DIHYDROBENZOCICLOALQUILOXIMETIL-OXAZOLOPIRIMIDINONES REPLACED, PREPARATION AND USE OF THE SAME
ES2582306T3 (en) Morphinan derivatives containing a carboxamide group as opioid receptor ligands
CL2022000125A1 (en) 2,4-diaminoquinazoline derivatives and medical uses thereof. (application divisional 202002253)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal